- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.11.25 | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 03.11.2025 | 1.033 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 03.11.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 03.11.2025.ISIN NameCA74971G4016 RF... ► Artikel lesen | |
| 03.11.25 | XFRA 7PL0: AUSSETZUNG/SUSPENSION | 173 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPROSTALUND AB 7PL0... ► Artikel lesen | |
| 24.10.25 | ProstaLund AB: PROSTALUND AB (publ) - Interim report January-September 2025 | 149 | GlobeNewswire (Europe) | Third quarterJuly 1 - September 30Net sales reached MSEK 2.2 (3.5)Operating profit/loss totaled MSEK -2.6 (-4.4)Loss after taxes MSEK -2.6 (-4.5)Earnings per share, before and after dilution amounted... ► Artikel lesen | |
| 15.10.25 | Delisting of ProstaLund AB from Nasdaq First North Growth Market | 242 | GlobeNewswire | ProstaLund AB has applied for its shares to be delisted from Nasdaq First North Growth Market.
Nasdaq Stockholm AB has approved the application and decided to delist the shares of ProstaLund... ► Artikel lesen | |
| PROSTALUND Aktie jetzt für 0€ handeln | |||||
| 12.09.25 | ProstaLund AB: ProstaLund enters collaboration agreement with the XEN Group for the market in the United Arab Emirates and Oman | 229 | GlobeNewswire (Europe) | ProstaLund has signed a collaboration agreement with the XEN Group, a prominent distributor of advanced innovative products with solid experience and contacts in the UAE and Oman. Through this partnership... ► Artikel lesen | |
| 10.09.25 | ProstaLund AB: ProstaLund enters collaboration agreement with Mayumana Healthcare for the Benelux market | 164 | GlobeNewswire (Europe) | ProstaLund has entered into a collaboration agreement with Mayumana Healthcare, a leading distributor of innovative urological solutions with strong expertise in the Benelux market. The partnership... ► Artikel lesen | |
| 21.08.25 | ProstaLund AB: ProstaLund AB - Interim Report January-June 2025 | 142 | GlobeNewswire (Europe) | April 1 - June 30Net sales reached MSEK 2.1 (2.8)Operating profit/loss totaled MSEK -6.3 (-7.2)Loss after taxes MSEK -6.5 (-7.1)Earnings per share, before and after dilution amounted to SEK -1.80 (-3.72)Cash... ► Artikel lesen | |
| 11.07.25 | The observation status for ProstaLund AB is updated | 279 | GlobeNewswire | On May 13, 2025, the shares in ProstaLund AB (the "Company") were given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
Today... ► Artikel lesen | |
| 01.07.25 | The observation status for ProstaLund AB is updated | 225 | GlobeNewswire | On May 13, 2025, the shares in ProstaLund AB (the "Company") were given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
On May... ► Artikel lesen | |
| 30.05.25 | ProstaLund AB: ProstaLund AB - Interim report January-March 2025 | 218 | GlobeNewswire (Europe) | Januari 1 - March 31Net sales reached SEK 3,7 million (3,5)Operating result amounted to -5,0 MSEK (-4,7)Profit after tax amounted to -5,0 MSEK (-4,8)Earnings per share before and after dilution amounted... ► Artikel lesen | |
| 23.05.25 | XFRA 7PL0: WIEDERAUFNAHME/RESUMPTION | 422 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| 23.05.25 | The observation status for ProstaLund AB is updated | 295 | GlobeNewswire | On May 13, 2025, the shares in ProstaLund AB (the "Company") were given observation status with reference to material adverse uncertainty in respect of the issuer's financial position.
On May... ► Artikel lesen | |
| 21.05.25 | Lift of Suspension in ProstaLund AB at FNSE | 313 | GlobeNewswire | 2025-05-21T15:00:36Z
Lifting of Suspension
At Trading Venue FNSE
Ended on:
2025-05-21T14:50:00Z
Ongoing: False
Comments: Nasdaq Stockholm has, to the
extent applicable, also decided to lift the suspension... ► Artikel lesen | |
| 20.05.25 | ProstaLund AB: First patients treated with CoreTherm Eagle | 291 | GlobeNewswire (Europe) | The first patients with benign prostatic hyperplasia have been successfully treated using our new CoreTherm® Eagle platform.
"We are very pleased that the first patients have been successfully treated... ► Artikel lesen | |
| 19.05.25 | XFRA 7PL0: AUSSETZUNG/SUSPENSION | 217 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPROSTALUND AB 7PL0... ► Artikel lesen | |
| 19.05.25 | Suspension of Trading in ProstaLund AB at FNSE | 283 | GlobeNewswire | 2025-05-19T07:01:39Z
Suspension
At Trading Venue FNSE
Due to Other
Ongoing:
True
Comments: Nasdaq Stockholm has, to the extent applicable, also decided to
suspend the trading in all other instruments... ► Artikel lesen | |
| 20.02.25 | ProstaLund AB: ProstaLund AB - Year-end report 2024 | 198 | GlobeNewswire (Europe) | "With several ongoing contract discussions for CoreTherm® Eagle, we are positive about the interest in our treatment and the upcoming international launch"
Fourth quarterOctober 1 - December 31Net sales... ► Artikel lesen | |
| 14.02.25 | ProstaLund AB: New study confirms the strong efficacy of CoreTherm in patients with large prostates | 289 | GlobeNewswire (Europe) | A newly published Danish study has evaluated the efficacy and safety of CoreTherm® in men with prostate sizes exceeding 100 grams. The median prostate size among participants was 126 g (range: 101-230... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIGENT BIO SOLUTIONS | 9,530 | 0,00 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Announces New Manufacturing Partnership to Strengthen Global Production Capability and Increase Margins | NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen | |
| BETA BIONICS | 30,470 | 0,00 % | Beta Bionics, Inc.: Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance | IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| GENEDX | 130,06 | +1,61 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| HEARTFLOW | 29,150 | -3,51 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 19,760 | +2,70 % | Alignment Healthcare Reports Third Quarter 2025 Results, Surpasses High-End of Guidance Across All Key Metrics | Reports Q3 revenue of $993.7 million, up 43.5% year-over-yearBeats high end of third quarter guidance and raises full-year outlook across all key metrics: membership, revenue, adjusted gross profit... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 8,170 | -2,62 % | Aveanna Healthcare Holdings, Inc: Aveanna Healthcare Holdings Announces Third Quarter Financial Results and Revised 2025 Outlook | Third Quarter Revenue was $621.9 million, a 22.2% increase over the prior year periodThird Quarter Net income was $14.1 million compared to Net loss of $42.8 million for the prior year periodAdjusted... ► Artikel lesen | |
| SIGHT SCIENCES | 7,930 | -0,88 % | Sight Sciences, Inc.: Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer | MENLO PARK, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 37,450 | 0,00 % | S&P Dow Jones Indices: BrightSpring Health Services Set to Join S&P SmallCap 600 | NEW YORK, Oct. 14, 2025 /PRNewswire/ -- BrightSpring Health Services Inc. (NASD: BTSG) will replace Veritex Holdings Inc. (NASD: VBTX) in the S&P SmallCap 600 effective... ► Artikel lesen | |
| OPTIMIZERX | 12,260 | -1,05 % | OptimizeRx Corporation: OptimizeRx Partners with Lamar Advertising to Reach Clinically Relevant Audiences Through Out-of-Home Healthcare Advertising | Strategic Partnership Combines OptimizeRx's Patented Micro-Neighborhood® Targeting Data with Lamar's Vast Nationwide OOH Network to Strengthen OOH Media for Healthcare Marketing WALTHAM, Mass., Sept.... ► Artikel lesen | |
| CERIBELL | 21,930 | 0,00 % | Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution | SUNNYVALE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a medical technology company focused on transforming the diagnosis and management of patients with... ► Artikel lesen | |
| EKSO BIONICS | 8,640 | 0,00 % | Applied Digital Corporation: Applied Digital to Spin Out Cloud Business, Proposes Business Combination with EKSO to Launch ChronoScale | DALLAS, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Applied Digital (NASDAQ: APLD), a designer, builder, and operator of high-performance, sustainably engineered data centers and colocation services for artificial... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 31,460 | 0,00 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| RXSIGHT | 10,420 | 0,00 % | RxSight, Inc. Announces Chief Financial Officer Transition | ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery... ► Artikel lesen | |
| PROGYNY | 25,690 | -0,58 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| BILLIONTOONE | 81,73 | -3,95 % | BillionToOne, Inc.: BillionToOne Reports Third Quarter 2025 Results | MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are... ► Artikel lesen |
Das Unternehmen PROSTALUND AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,001 Euro.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROSTALUND AB finden Sie auf Wallstreet Online.